Literature DB >> 6667627

Plasma concentrations of salbutamol after an oral slow-release preparation.

J G Maconochie, P Fowler.   

Abstract

Studies were carried out to investigate the plasma concentrations of salbutamol after administration of a slow-release formulation (8 mg) compared with those after 1 and after 2 standard 4 mg tablets. In the first study, 9 subjects received, at random, either the slow-release tablet or a single standard tablet. Blood samples were taken and histamine challenge tests were carried out before and at fixed time intervals after drug administration. The procedures were repeated after an interval of at least 5 days with the alternative treatment. In the second study, plasma concentrations were measured in 5 of the subjects before and after taking 2 standard 4 mg tablets. The results showed that there was slower attainment of peak plasma concentrations after the slow-release formulation compared to those after one 4 mg and two 4 mg standard tablets. In addition, the 8 mg slow-release formulation produced lower peak plasma concentrations than did two 4 mg standard tablets. Protection against a bronchoconstricting histamine challenge lasted at least twice as long after the slow-release compared with after a single 4 mg standard tablet.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6667627     DOI: 10.1185/03007998309109811

Source DB:  PubMed          Journal:  Curr Med Res Opin        ISSN: 0300-7995            Impact factor:   2.580


  5 in total

1.  Pharmacokinetics of oral salbutamol controlled-release in Asian patients with asthma.

Authors:  W C Tan; H S Lee
Journal:  Eur J Clin Pharmacol       Date:  1991       Impact factor: 2.953

Review 2.  Salbutamol in the 1980s. A reappraisal of its clinical efficacy.

Authors:  A H Price; S P Clissold
Journal:  Drugs       Date:  1989-07       Impact factor: 9.546

3.  Pharmacokinetics and absolute bioavailability of salbutamol in healthy adult volunteers.

Authors:  D A Goldstein; Y K Tan; S J Soldin
Journal:  Eur J Clin Pharmacol       Date:  1987       Impact factor: 2.953

4.  Plasma concentrations and effects of salbutamol administered orally to patients with cystic fibrosis.

Authors:  R Demnati; M C Michoud; A Jeanneret-Grosjean; H Ong; P Du Souich
Journal:  Br J Clin Pharmacol       Date:  1995-10       Impact factor: 4.335

Review 5.  Clinical pharmacokinetics of beta-agonists.

Authors:  D J Morgan
Journal:  Clin Pharmacokinet       Date:  1990-04       Impact factor: 6.447

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.